Evidence map›Paper›PMID 38757074›Full record

ArticleInternational journal of particle therapy2024

Long-Term Outcomes Following Definitive or Adjuvant Proton Radiotherapy for Adenoid Cystic Carcinoma.

Etzer Augustin, Adam L Holtzman, Roi Dagan, Curtis M Bryant, Daniel J Indelicato, Christopher G Morris, Rohan L Deraniyagala, Rui P Fernandes, Anthony M Bunnell, Stacey M Nedrud and 1 more

Abstract read
In one paragraph

Article in International journal of particle therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Etzer AugustinDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Adam L HoltzmanDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA.
Roi DaganDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Curtis M BryantDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Daniel J IndelicatoDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Christopher G MorrisDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Rohan L DeraniyagalaDepartment of Radiation Oncology, Corewell Health/Beaumont Hospital, Royal Oak, Michigan, USA.
Rui P FernandesDepartment of Oral and Maxillofacial Surgery, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA.
Anthony M BunnellDepartment of Oral and Maxillofacial Surgery, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA.
Stacey M NedrudDepartment of Oral and Maxillofacial Surgery, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA.
William M MendenhallDepartment of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Adenoid cystic carcinoma (ACC) is a rare malignancy accounting for 1% of all head and neck cancers. Treatment for ACC has its challenges and risks, yet few outcomes studies exist. We present long-term outcomes of patients with ACC of the head and neck treated with proton therapy (PT). Materials and Methods: Under an institutional review board-approved, single-institutional prospective outcomes registry, we reviewed the records of 56 patients with de novo, nonmetastatic ACC of the head and neck treated with PT with definitive ( Results: With a median follow-up of 6.2 years (range, 0.9-14.7), the 5-year local-regional control (LRC), disease-free survival, cause-specific survival, and overall survival rates were 88%, 85%, 89%, and 89%, respectively. Intracranial extension ( Conclusion: This is the largest sample size with the longest median follow-up to date of patients with ACC treated with PT. PT can provide excellent disease control for ACC of the head and neck with acceptable toxicity. T4 disease, intracranial involvement, and gross residual disease at the time of PT following either biopsy or subtotal resection were significant prognostic features for worse outcomes.

Indexed as

Adenoid cystic carcinomaHead and neckProton therapyRadiation therapySalivary gland

Identifiers

PMID38757074
PMCPMC11096740

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.